Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells.

Sesumi Y, Suda K, Mizuuchi H, Kobayashi Y, Sato K, Chiba M, Shimoji M, Tomizawa K, Takemoto T, Mitsudomi T.

Lung Cancer. 2017 Feb;104:85-90. doi: 10.1016/j.lungcan.2016.12.012. Epub 2016 Dec 21.

PMID:
28213007
2.

MEK inhibitors against MET-amplified non-small cell lung cancer.

Chiba M, Togashi Y, Tomida S, Mizuuchi H, Nakamura Y, Banno E, Hayashi H, Terashima M, De Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K.

Int J Oncol. 2016 Dec;49(6):2236-2244. doi: 10.3892/ijo.2016.3736. Epub 2016 Oct 17.

3.

Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression.

Sato K, Suda K, Shimizu S, Sakai K, Mizuuchi H, Tomizawa K, Takemoto T, Nishio K, Mitsudomi T.

PLoS One. 2016 Apr 21;11(4):e0154186. doi: 10.1371/journal.pone.0154186. eCollection 2016.

4.

Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer.

Mizuuchi H, Suda K, Murakami I, Sakai K, Sato K, Kobayashi Y, Shimoji M, Chiba M, Sesumi Y, Tomizawa K, Takemoto T, Sekido Y, Nishio K, Mitsudomi T.

Cancer Sci. 2016 Apr;107(4):461-8. doi: 10.1111/cas.12905. Epub 2016 Mar 28.

5.

Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2.

Terashima M, Togashi Y, Sato K, Mizuuchi H, Sakai K, Suda K, Nakamura Y, Banno E, Hayashi H, De Velasco MA, Fujita Y, Tomida S, Mitsudomi T, Nishio K.

Clin Cancer Res. 2016 Jul 15;22(14):3663-71. doi: 10.1158/1078-0432.CCR-15-2093. Epub 2016 Jan 29.

6.

Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer.

Suda K, Murakami I, Sakai K, Tomizawa K, Mizuuchi H, Sato K, Nishio K, Mitsudomi T.

Lung Cancer. 2016 Jan;91:36-40. doi: 10.1016/j.lungcan.2015.11.016. Epub 2015 Nov 25.

PMID:
26711932
7.

MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor.

Togashi Y, Mizuuchi H, Tomida S, Terashima M, Hayashi H, Nishio K, Mitsudomi T.

Lung Cancer. 2015 Dec;90(3):590-7. doi: 10.1016/j.lungcan.2015.10.020. Epub 2015 Nov 4.

PMID:
26547802
8.

Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.

Suda K, Murakami I, Sakai K, Mizuuchi H, Shimizu S, Sato K, Tomizawa K, Tomida S, Yatabe Y, Nishio K, Mitsudomi T.

Sci Rep. 2015 Sep 24;5:14447. doi: 10.1038/srep14447.

9.

Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.

Furugaki K, Fukumura J, Iwai T, Yorozu K, Kurasawa M, Yanagisawa M, Moriya Y, Yamamoto K, Suda K, Mizuuchi H, Mitsudomi T, Harada N.

Int J Cancer. 2016 Feb 15;138(4):1024-32. doi: 10.1002/ijc.29848. Epub 2015 Oct 13.

10.

Solitary pulmonary metastasis from malignant melanoma of the bulbar conjunctiva presenting as a pulmonary ground glass nodule: Report of a case.

Mizuuchi H, Suda K, Kitahara H, Shimamatsu S, Kohno M, Okamoto T, Maehara Y.

Thorac Cancer. 2015 Jan;6(1):97-100. doi: 10.1111/1759-7714.12124. Epub 2015 Jan 7.

11.

EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.

Kobayashi Y, Togashi Y, Yatabe Y, Mizuuchi H, Jangchul P, Kondo C, Shimoji M, Sato K, Suda K, Tomizawa K, Takemoto T, Hida T, Nishio K, Mitsudomi T.

Clin Cancer Res. 2015 Dec 1;21(23):5305-13. doi: 10.1158/1078-0432.CCR-15-1046. Epub 2015 Jul 23.

12.

An activating ALK gene mutation in ALK IHC-positive/FISH-negative nonsmall-cell lung cancer.

Togashi Y, Mizuuchi H, Kobayashi Y, Hayashi H, Terashima M, Sakai K, Banno E, Mizukami T, Nakamura Y, de Velasco MA, Fujita Y, Tomida S, Mitsudomi T, Nishio K.

Ann Oncol. 2015 Aug;26(8):1800-1. doi: 10.1093/annonc/mdv240. Epub 2015 May 22. No abstract available.

PMID:
26002608
13.

Collateral chemoresistance to anti-microtubule agents in a lung cancer cell line with acquired resistance to erlotinib.

Mizuuchi H, Suda K, Sato K, Tomida S, Fujita Y, Kobayashi Y, Maehara Y, Sekido Y, Nishio K, Mitsudomi T.

PLoS One. 2015 Apr 14;10(4):e0123901. doi: 10.1371/journal.pone.0123901. eCollection 2015.

14.

Recent evidence, advances, and current practices in surgical treatment of lung cancer.

Suda K, Sato K, Mizuuchi H, Kobayashi Y, Shimoji M, Tomizawa K, Takemoto T, Iwasaki T, Sakaguchi M, Mitsudomi T.

Respir Investig. 2014 Nov;52(6):322-9. doi: 10.1016/j.resinv.2014.06.003. Epub 2014 Jul 11. Review.

PMID:
25453375
15.

CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation.

Suda K, Mizuuchi H, Murakami I, Uramoto H, Tanaka F, Sato K, Takemoto T, Iwasaki T, Sekido Y, Yatabe Y, Mitsudomi T.

Lung Cancer. 2014 Aug;85(2):147-51. doi: 10.1016/j.lungcan.2014.05.018. Epub 2014 Jun 2.

PMID:
24939008
16.

The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor.

Suda K, Mizuuchi H, Sato K, Takemoto T, Iwasaki T, Mitsudomi T.

Int J Cancer. 2014 Aug 15;135(4):1002-6. doi: 10.1002/ijc.28737. Epub 2014 Feb 4.

17.

Genetic and Prognostic Differences of Non-small Cell Lung Cancer between Elderly Patients and Younger Counterparts.

Suda K, Tomizawa K, Mizuuchi H, Ito S, Kitahara H, Shimamatsu S, Kohno M, Yoshida T, Okamoto T, Maehara Y, Yatabe Y, Mitsudomi T.

Aging Dis. 2012 Dec;3(6):438-43. Epub 2012 Oct 23.

18.

Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny.

Suda K, Mizuuchi H, Maehara Y, Mitsudomi T.

Cancer Metastasis Rev. 2012 Dec;31(3-4):807-14. doi: 10.1007/s10555-012-9391-7. Review.

PMID:
22736441
19.

Current-stimulated release of solutes solubilized in water-immiscible room temperature ionic liquids (RTILs).

Jaitely V, Mizuuchi H, Florence AT.

J Drug Target. 2010 Dec;18(10):787-93. doi: 10.3109/1061186X.2010.525653.

PMID:
21047272
20.

Topics on transporter-mediated renal excretion and drug-drug interaction.

Mizuuchi H.

Nihon Yakurigaku Zasshi. 2010 Jan;135(1):30-3. doi: 10.1254/fpj.135.30. Review. Japanese. No abstract available.

PMID:
20075568
21.

Room temperature ionic liquids and their mixtures: potential pharmaceutical solvents.

Mizuuchi H, Jaitely V, Murdan S, Florence AT.

Eur J Pharm Sci. 2008 Apr 23;33(4-5):326-31. doi: 10.1016/j.ejps.2008.01.002. Epub 2008 Jan 10.

PMID:
18291630
22.

Intramuscular absorption and biodistribution of dexamethasone from non-aqueous emulsions in the rat.

Suitthimeathegorn O, Turton JA, Mizuuchi H, Florence AT.

Int J Pharm. 2007 Mar 1;331(2):204-10. Epub 2006 Dec 3.

PMID:
17250983
23.

A study of clinical features of cough variant asthma.

Okada C, Horiba M, Matsumoto H, Torigoe R, Mizuuchi H, Murao M, Soda R, Takahashi K, Kimura G, Tanimoto Y.

Int Arch Allergy Immunol. 2001;125 Suppl 1:51-4.

PMID:
11408774
24.

Transport of procainamide via H(+)/tertiary amine antiport system in rabbit intestinal brush-border membrane.

Katsura T, Mizuuchi H, Hashimoto Y, Inui KI.

Am J Physiol Gastrointest Liver Physiol. 2000 Oct;279(4):G799-805.

25.

Transepithelial transport of diphenhydramine across monolayers of the human intestinal epithelial cell line Caco-2.

Mizuuchi H, Katsura T, Hashimoto Y, Inui K.

Pharm Res. 2000 May;17(5):539-45.

PMID:
10888305
26.

Diphenhydramine transport by pH-dependent tertiary amine transport system in Caco-2 cells.

Mizuuchi H, Katsura T, Ashida K, Hashimoto Y, Inui K.

Am J Physiol Gastrointest Liver Physiol. 2000 Apr;278(4):G563-9.

27.

Preferential salivary-type hypoamylasemia in obese children.

Mizuuchi H, Taketa K.

Acta Med Okayama. 1999 Jun;53(3):119-22.

PMID:
10410788
28.

Transport characteristics of diphenhydramine in human intestinal epithelial Caco-2 cells: contribution of pH-dependent transport system.

Mizuuchi H, Katsura T, Saito H, Hashimoto Y, Inui KI.

J Pharmacol Exp Ther. 1999 Jul;290(1):388-92.

29.

Effects of corticotropin-releasing factor on feeding and pancreatic polypeptide response in the dog.

Okita M, Inui A, Inoue T, Mizuuchi H, Banno K, Baba S, Kasuga M.

J Endocrinol. 1998 Feb;156(2):359-64.

30.

Antitumor effect of carboplatin combined with radiation on tumors in mice.

Aratani Y, Yoshiga K, Mizuuchi H, Jo A, Tanimoto K, Sakurai K.

Anticancer Res. 1997 Jul-Aug;17(4A):2535-8.

PMID:
9252676
31.

Antitumor effect of carboplatin combined with hyperthermia on Ehrlich-ascites tumor in vivo.

Mizuuchi H, Yoshiga K, Sakurai K, Tsumura M, Takada K.

Anticancer Res. 1996 Jan-Feb;16(1):381-7.

PMID:
8615640
32.

Enhancement of antitumor effects of new analogue of platinum, cis-diammine (glycolato) platinum (254-S) combined with hyperthermia in vivo.

Jo A, Sakurai K, Tsumura M, Mizuuchi H, Yoshiga K, Takada K.

Anticancer Res. 1996 Jan-Feb;16(1):301-4.

PMID:
8615625
33.

[Is CA125 useful in the management of recurrence of endometrial carcinoma?].

Sato K, Mizuuchi H, Mori Y, Okamura N, Endo T, Ito E, Kudo R.

Nihon Sanka Fujinka Gakkai Zasshi. 1995 Sep;47(9):917-24. Japanese.

PMID:
7594902
34.

High incidence of point mutation in K-ras codon 12 in carcinoma of the fallopian tube.

Mizuuchi H, Mori Y, Sato K, Kamiya H, Okamura N, Nasim S, Garrett CT, Kudo R.

Cancer. 1995 Jul 1;76(1):86-90.

PMID:
8630881
35.

[A report of two endometrial cancer cases in that low-dose aspirin was effective for hypercoagulopathy caused by medroxyprogesterone acetate].

Sato K, Mori Y, Okamura N, Mizuuchi H.

Nihon Sanka Fujinka Gakkai Zasshi. 1995 Mar;47(3):291-4. Japanese. No abstract available.

PMID:
7699291
36.

[Primary clear cell carcinoma arising in cystic adenomyosis of the uterus--a case report].

Mori Y, Inoue Y, Sakai K, Koizumi M, Okamura N, Sato K, Mizuuchi H.

Nihon Sanka Fujinka Gakkai Zasshi. 1994 Sep;46(9):915-7. Japanese. No abstract available.

PMID:
7963893
37.

[Management of the uterine endometrial cancer cases whose cytological and histologic specimens cannot be obtained from the uterine cavity--assessment by CA125 or vaginal ultrasonography].

Sato K, Mizuuchi H, Mori Y, Okamura N, Endo T, Kudo R, Tsukamoto K.

Nihon Sanka Fujinka Gakkai Zasshi. 1994 Jun;46(6):517-24. Japanese.

PMID:
8040624
38.

[The factors involved in invasive ability of endometrial carcinoma cells].

Mori Y, Mizuuchi H, Sato K, Okamura N, Kudo R.

Nihon Sanka Fujinka Gakkai Zasshi. 1994 Jun;46(6):509-16. Japanese.

PMID:
8040623
39.

[Usefulness of CA125 determination in the diagnosis of lymph node metastasis in post menopausal uterine endometrial carcinoma].

Sato K, Mizuuchi H, Mori Y, Okamura N, Kudo R.

Nihon Sanka Fujinka Gakkai Zasshi. 1994 Apr;46(4):331-6. Japanese.

PMID:
8151175
40.

Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium.

Mizuuchi H, Nasim S, Kudo R, Silverberg SG, Greenhouse S, Garrett CT.

Cancer Res. 1992 May 15;52(10):2777-81.

41.

[Significance of 5-S-cysteinyldopa on primary malignant melanoma of the female genital organs].

Takehara M, Mizuuchi H, Ito E, Hayakawa O, Takashima S, Nei H, Kudo R, Horikoshi T, Ito S.

Nihon Sanka Fujinka Gakkai Zasshi. 1992 Mar;44(3):369-72. Japanese. No abstract available.

PMID:
1607763
42.

Peritoneal washing cytology at second-look laparotomy in cisplatin-treated ovarian cancer patients.

Kudo R, Takashina T, Ito E, Mizuuchi H, Sagae S, Moriwaka O, Tamagawa A.

Acta Cytol. 1990 Jul-Aug;34(4):545-8.

PMID:
2375223
43.

A case-control study of uterine endometrial cancer in Japanese and Finn.

Kudo R, Punnonen R, Mizuuchi H, Teisala K, Kanemoto T.

Nihon Sanka Fujinka Gakkai Zasshi. 1990 Jul;42(7):747-52.

PMID:
2212813
44.

Minimal-deviation adenocarcinoma (adenoma malignum) of the uterine cervix; four case reports.

Kudo R, Sagae S, Kusanagi T, Mizuuchi H, Hayakawa O, Hashimoto M.

Eur J Obstet Gynecol Reprod Biol. 1990 Jan-Feb;34(1-2):179-88.

PMID:
2303151
45.
46.

Immunohistological identification of T and B cells in normal and malignant tissues of the uterine endometrium.

Mizuuchi H, Kudo R, Tamura H, Kumai K, Sato K, Hashimoto M.

Nihon Sanka Fujinka Gakkai Zasshi. 1989 Mar;41(3):349-56.

PMID:
2659692
47.

[Neurological disturbances in the lower legs subsequent to vaginal hysterectomy].

Matsumoto M, Narimatsu E, Takahashi I, Namiki A, Kudo R, Mizuuchi H.

Masui. 1988 Nov;37(11):1394-9. Japanese. No abstract available.

PMID:
2852265
48.

Identification of transferrin receptor in cervical and endometrial tissues.

Mizuuchi H, Kudo R, Tamura H, Tsukahara K, Tsumura N, Kumai K, Sato K.

Gynecol Oncol. 1988 Oct;31(2):292-300.

PMID:
3169618
50.

[Vaginal radical hysterectomy with and without systemic extraperitoneal pelvic lymphadenectomy for cervical cancer. A report of 666 patients operated upon between the years 1957 and 1973 (author's transl)].

Akashi E, Kudou R, Kusanagi T, Adachi K, Mizuuchi H, Kawase N, Hashimoto M.

Nihon Sanka Fujinka Gakkai Zasshi. 1980 May;32(5):567-76. Japanese.

PMID:
7240845

Supplemental Content

Loading ...
Support Center